Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. (AMS: VVY) is trading at €1.11, about ₹121 at today's EUR/INR rate, as of 25 Sep 2026, 11:35 AM ET. Indian residents can buy Vivoryon Therapeutics from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
€1.08
Today's high
€1.12
52 week low
€1.00
52 week high
€1.84
VVY opened at €1.12, closed previously at €1.11, and has traded between €1.00 and €1.84 over the past 52 weeks.
About
Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel treatments for Alzheimer's disease. The company's therapeutic pipeline primarily focuses on mitigating Alzheimer's by targeting and preventing the formation of toxic pyroglutamate-Abeta (pGlu-Abeta). Its flagship compound, PQ912, a small molecule QC inhibitor, has successfully concluded Phase IIb clinical trials for both Alzheimer's disease and various cancer indications. Additionally, Vivoryon is advancing PQ1565, another small molecule (a glutaminyl-peptide cyclotransferase-like inhibitor), through preclinical development, specifically for cancer therapy. Beyond its small molecule programs, the company is also developing a monoclonal antibody designed to improve the clearance of pGlu-Abeta from the body. To bolster its research and development efforts, Vivoryon has forged several key partnerships, including collaborations with the University Medical Center Schleswig-Holstein for cancer immunotherapy discovery, Nordic Bioscience for the clinical progression of PQ912 in Alzheimer's, and the Fraunhofer Institute for cell therapy and immunology. Furthermore, a significant regional licensing agreement with Simcere Pharmaceutical Group Ltd. aims to develop and commercialize treatments for Alzheimer's disease by targeting the neurotoxic amyloid species N3pE (pGlu-Abeta). Established in 1997, Vivoryon Therapeutics N.V. maintains its headquarters in Halle, Germany.
Key statistics
Avg. volume
50.12K
Market cap
€32.87M
P/E Ratio
-4.83
Price-to-sales ratio
0.00
Enterprise value
€30.50M
Free cash flow yield
-21.62%
Debt-to-equity ratio
0.05
Return on equity
-215.13%
ROIC
-198.79%
Beta
1.44
Dividend yield
0.00%
Last dividend
€0.00
Financial overview
Revenue
€0.00
Earnings per share
-€0.33
Free cash flow
-€8.46M
Net profit margin
0.00%
Gross margin
0.00%
EBITDA
-€9.03M
Revenue growth
—
Similar securities
This is not an investment recommendation
How to buy Vivoryon Therapeutics from India
Indian residents can buy Vivoryon Therapeutics shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to EUR.
Search for Vivoryon Therapeutics and place an order
Find Vivoryon Therapeutics by name or by its ticker, VVY, and choose an order type. Vivoryon Therapeutics trades 12:30 pm – 9:00 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Vivoryon Therapeutics position in EUR and INR. Vivoryon Therapeutics pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Vivoryon Therapeutics from India
Trading and taxes when buying Vivoryon Therapeutics from India
Trading and limits
- Trading hours
- 9:00 am – 5:30 pm CET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneVivoryon Therapeutics does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy Vivoryon Therapeutics stock?
Yes. Vivoryon Therapeutics (VVY) has been listed on Euronext Amsterdam since 2014, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to EUR. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one Vivoryon Therapeutics share cost in rupees?
One Vivoryon Therapeutics share is €1.11 — about ₹121 at an EUR/INR rate of 109.20 on 26 Sep 2026. Both the Vivoryon Therapeutics price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Vivoryon Therapeutics from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
How are gains on Vivoryon Therapeutics shares taxed in India?
Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the EUR/INR rate on the purchase and the sale date, so the rupee move counts alongside the Vivoryon Therapeutics price. Paasa issues a capital-gains statement for your return.
Does Vivoryon Therapeutics pay a dividend?
No. Vivoryon Therapeutics does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Vivoryon Therapeutics from India?
Euronext Amsterdam trades 12:30 pm – 9:00 pm IST in Indian time. The window shifts to 1:30 pm – 10:00 pm IST when the Netherlands is on standard time. Orders can only execute during that window.
Is Vivoryon Therapeutics a Netherlands company, and does that change how it is taxed?
Vivoryon Therapeutics trades on Euronext Amsterdam in EUR, but the company is domiciled in Germany. Vivoryon Therapeutics trades as an ordinary share listed directly in the Netherlands, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare Vivoryon Therapeutics shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Vivoryon Therapeutics holding, its cost and its closing value.
How do I sell Vivoryon Therapeutics and bring the money back to India?
You sell during market hours (12:30 pm – 9:00 pm IST) and the proceeds settle in EUR in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.
Does the rupee rate affect what I make on Vivoryon Therapeutics?
Yes. Vivoryon Therapeutics is priced in EUR, so your rupee outcome combines the EUR move with the EUR/INR move between the day you remit and the day you convert back. Both directions are reflected in the capital-gains statement Paasa issues.